



PASPCR

Newsletter

Volume 7 Number 2

June, 1999

Introduction . . .

The **PASPCR Newsletter** is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to it. If you attend a scientific meeting at which you heard work which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. Any information on upcoming meetings of interest will also be included. We also want to note any change of affiliation or address that you may have had. This is **your Newsletter**, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to Bill Oetting, preferably by Email to bill@lenti.med.umn.edu.

The **PASPCR Web** page is the major, up-to-date source of current information for the **PASPCR** membership. The URL address to our home page is <http://www.cbc.umn.edu/paspcr>. This is a very active web-page, and as of May, the **PASPCR** home page has had over 13,000 'hits'. The **PASPCR Web** page contains information about the **PASPCR** including the goals, ByLaws and Rules of the Society, future meetings, past issues of the **PASPCR Newsletter** as well as links to other related sites including the InterPig DataBase, the International Federation of Pigment Cell Societies (**IFPCS**) and the regional Pigment Cell Societies from Europe and Japan. In addition, an updated **PASPCR** membership directory is available on the **PASPCR Web** page; please notify us if you wish any or all of your information to be modified or deleted on that site. The **PASPCR** home page also includes positions available and positions wanted. Postings for Positions Available is open to all individuals so long as the position is related to pigment cell research. Postings for Positions Wanted will be open only to members of the **PanAmerican Society for Pigment Cell Research** or its sister societies (**JSPCR** and **ESPCR**). Send postings to Bill Oetting at bill@lenti.med.umn.edu. Please provide an expiration data for any submitted postings. If there is additional information that you wish to have added to this web page, please let us know. Send any comments and/or suggestions to the **PASPCR** WebMaster, Bill Oetting at bill@lenti.med.umn.edu.

IN THIS ISSUE

Introduction.....	p 1
PASPCR Contact Information.....	p 2
Calendar of Events.....	p 2
Corporate Sponsors.....	p 3
PASPCR Council Election Results.....	p 3
Scientific Program for the 17th IPCC.....	p 3
Update IX th PASPCR Annual Meeting.....	p 7
Positions Wanted / Available.....	p 8
Members in the News.....	p 9
Bibliography.....	p 9

**PanAmerican Society for
Pigment Cell Research**

c/o **Dr. James J. Nordlund / Raymond Boissy**
Department of Dermatology
University of Cincinnati
231 Bethesda Avenue
Cincinnati, OH 45267-0592
FAX: (513) 558-0198

Officers

Richard A. King
President
Zalfa Abdel-Malek
President-Elect
James J. Nordlund
Secretary/Treasurer

Council Members

Gregory S. Barsh
Jean L. Bologna
Meenhard Herlyn
Helene Z. Hill
M. Lynn Lamoreux
Estela E. Medrano
William J. Pavan
John M. Pawelek
Giselle Thibaudeau

IFPCS Representative

Sally Frost-Mason
past-President PASPCR

The **PASPCR Newsletter** is published quarterly; for further information or to submit articles, contact:

Publications Committee:

Meenhard Herlyn, DVM

The Wistar Institute
Program of Cellular and Molecular Biology
3601 Spruce Street
Philadelphia, PA 19104-4268
Phone: (215) 898-3950
FAX: (215) 898-0980

Helene Z. Hill, PhD

New Jersey Medical School
Dept of Radiology - MSB E586
185 South Orange Avenue
Newark, NJ 07103-2714
Phone: (201) 982-3421
FAX: (201) 982-4559

Giselle Thibaudeau, PhD (Chair)

Mississippi State University
Department of Biological Sciences
Harned Hall
Mississippi State, MS 39762
Phone: (601) 325-7572
FAX: (601) 325-7939

Calendar of Events :

Oct 30 - Nov 3, 1999 XVIIth International Pigment Cell Conference, to be held in Nagoya, Japan (contact: Dr. Shosuke Ito, Fujita Health University School of Health Sciences, Toyoake, Aichi 470-11, Japan; Phone: +81-562-93-2595; Fax: +81-562-93-4595; Email: sito@fujita-hu.ac.jp)

Jun 25 - 28, 2000 IXth Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in College Station, TX (contact: Dr. Lynn Lamoreux, Department of Veterinary Pathobiology, The Texas Veterinary Medical Center, Texas A & M University, College Station, TX 77843-4467; Phone: (409) 845-6084; FAX: (409) 845-9972; Email: LLAMOREUX@VETMED.TAMU.EDU)

Corporate Sponsors

by James J Nordlund / Raymond Boissy

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons

ICN Pharmaceuticals, Inc
Lawrence M Gelb Research
Foundation of Clairol, Inc
Ortho Pharmaceutical Corp

SILVER Corporate Patrons

Avon Products, Inc
Chesebrough-Pond's USA Co
Procter and Gamble Co
Shiseido Co, Ltd

Corporate Patrons

Combe, Inc.
Galderma Laboratories, Inc
Stiefel Laboratories

PASPCR Council Election Results

by James J Nordlund / Raymond Boissy

Congratulations to the new Council Members elected to 3 year terms.

Meehard Herlyn

Helene Z. Hill

Giselle Thibadeau

And congratulations to our new President-Elect.

Zalfa Abdel-Malek

Scientific Program for the 17th International Pigment Cell Conference To be held in Nagoya, Japan, October 30th to November 3rd, 1999

There will be 5 Special Lectures (SL), 13 Symposia (plenary or concurrent), 1 Special Symposium (with 5 Hot Topics talks), 2 Evening Sessions, 2 Poster Sessions, a Public Forum, and 4 Satellite Meetings. Each Symposium will consist of 1 Keynote Lecture (KL), 2 Invited Lectures, and 3 papers selected from submitted abstracts. Participants are encouraged to compete for the 3 papers to be presented orally in each Symposium. **Note:** Only a single projector will be available in each Symposium Room.

For more information, see the 17th IPCC web site at <http://www.fujita-hu.ac.jp/IPCCNagoya/> or contact the Meeting Chair, Dr. Shosuke Ito at: **Fujita Health University School of Health Sciences, Toyoake, Aichi 470-11, Japan; Phone: +81-562-93-2595; Fax: +81-562-93-4595; Email: sito@fujita-hu.ac.jp**

1st Day, Saturday, October 30, 1999

09:30 - 11:00 Regional Society Council Meetings

10:00 - 20:00 Registration

11:00 - 13:00 IFPCS Council Meeting 1

13:00 - 17:00 Satellite Meeting 1

SMI Vitiligo: A Manifestation of Apoptosis?

Organizers: Seung-Kyung Hann, James J. Nordlund, and Jean P. Ortonne

13:00 - 17:00 Satellite Meeting 2
SM2 Genetics of Pigmentation
Organizers: Richard A. King and Yasushi Tomita

15:00 - 20:00 Poster Set Up

18:00 - 19:30 Welcome Reception (at the NCC)

2nd Day, Sunday, October 31, 1999

08:00 - 18:00 Registration

08:00 - 12:00 Poster Set Up

08:00 - 08:30 Light Breakfast

08:30 - 08:40 Opening Remarks

08:40 - 09:20 Special Lecture 1

SL1 Molecular Biology of Catecholamines and Tetrahydrobiopterin Cofactor
Toshiharu Nagatsu

09:20 - 10:00 Special Lecture 2

SL2 Dual Control of Melanogenesis and Melanoma Growth: Molecular to Clinical Level and the Reverse
Yutaka Mishima

10:00 - 10:30 Break

10:30 - 12:30 Plenary Symposium 1

PS1 Biochemistry of Melanogenesis, Melanosomes, and Melanocytes
KL1 Induction and Activation of Tyrosinase Gene Family for Melanosome Biosynthesis and Melanocyte Differentiation
Kowichi Jimbow

12:30 - 13:30 Lunch and Poster Viewing

13:30 - 14:30 Poster Viewing

12:30 - 14:30 Tea Ceremony (at Shiratori Garden)

12:30 - 14:30 Pigment Cell Research Editor's Meeting

14:30 - 16:30 Concurrent Symposia 1, 2

CS1 Vitiligo and Related Pigmentary Disorders
KL2 Intrinsic and Extrinsic Pathomechanisms in Vitiligo
Alain Taieb

CS2 Chemistry and Biophysics of Melanin and Melanogenesis

KL3 Chemical Analysis of Melanins and Its Application to the Study of Melanogenesis Regulation
Shosuke Ito

16:30 - 16:45 Break

16:45 - 18:45 Plenary Symposium 2

PS2 Basic Biology of Melanoma
KL4 The Biology of Melanoma Development
Meenhard Herlyn

18:45 - 20:00 Evening Sessions 1, 2

ES1 Melanoblasts, Melanocytes and Melanoma Cells: What Is in Common and What Is Not?
Dorothy Bennett, Meenhard Herlyn, Tomohisa Hirobe

ES2 Advances in Melanoma Management

Alistair J. Cochran, Toshiro Kageshita, Frank L. Meyskens, Jr.

3rd Day, Monday, November 1, 1999

08:00 - 18:00 Registration

08:00 - 08:30 Light Breakfast

08:30 - 10:30 Plenary Symposium 3

PS3 Molecular Biology of Pigmentation and Pigment Cells

KL5 Regulation of Pigment Cell-Specific Gene Expression by MITF

Shigeki Shibahara

10:30 - 10:50 Break

10:50 - 11:30 Special Lecture 3 "Seiji Memorial Lecture"

SL3 Melanoma Genes and the Senescence and Immortalization of Melanocytes

Dorothy C. Bennett

11:30 - 12:00 IFPCS General Assembly

12:00 - 13:00 Regional Society General Assemblies

13:00 - 14:30 Poster Session 1

Odd-numbered Poster Authors

14:30 - 16:30 Concurrent Symposia 3, 4

CS3 Melanoma: Ultraviolet Light, Diagnosis and Treatment

KL6 Understanding Regulation of NF κ B as a Basis for Melanocyte Transformation and Melanoma Cell Therapeutic Resistance

Frank L. Meyskens, Jr.

CS4 Comparative Biology of Pigmentation

KL7 Dynamics of Pigment Cells in Poikilothermal Vertebrates

Noriko Oshima

16:30 - 16:45 Break

16:45 - 18:45 Plenary Symposium 4

PS4 Inter/Intracellular Signaling Pathways in Melanocytes

KL8 Microenvironment-dependent Regulation of Melanocyte Differentiation

Shin-Ichi Nishikawa

4th Day, Tuesday, November 2, 1999

08:00 - 08:30 Light Breakfast

08:30 - 09:10 Special Lecture 4 **Presidential Address**

SL4 The Melanosome: The Perfect Model for Cellular Responses to the Environment

Vincent J. Hearing

09:10 - 09:50 Special Lecture 5

SL5 Role of Neuropilin in Development of Peripheral Nervous System

Hajime Fujisawa

09:50 - 10:10 Break

10:10 - 12:10 Concurrent Symposia 5, 6

CS5 Melanocyte Photobiology /Chemistry and UV Protection

KL9 Tanning as Part of the SOS Response

Barbara A. Gilchrest

CS6 Ocular/Extracutaneous Melanin and Melanogenesis

KL10 Melanogenesis and Growth of Ocular Pigment Cells

Dan-Ning Hu

12:30- 17:30 Excursions

EX1 Castles in Nagoya

EX2 Culture in Nagoya

EX3 Industries in Nagoya

18:00 - 19:00 Reception (at the Miyako Hotel)

19:00 - 21:30 Awards Banquet

5th Day, Wednesday (Holiday), November 3, 1999

08:00 - 08:30 Light Breakfast

08:30 - 10:10 Plenary Symposium 5

"Hot Topics" Symposium

PS5 Recent Advances in Pigment Cell Research

10:10 - 10:30 Break

10:30 - 12:30 Concurrent Symposia 7, 8

CS7 Genetics of Pigmentation

KL11 Biochemical and Genetic Studies of Endogenous Melanocortin Receptor Antagonists

Gregory S. Barsh

CS8 Control of Hyper / Hypo-pigmentation

KL12 Keratinocyte/Melanocyte Co-cultures and Pigmented Reconstructed Epidermis as Models to Study Skin Pigmentation and Its Modulation

Rainer Schmidt

12:30 - 13:30 Lunch

12:30 - 13:30 Women Scientists Forum (with lunch)

13:30 - 15:00 IFPCS Council Meeting 2

13:30 - 15:00 Poster Session 2

Even-numbered Poster Authors

15:00 - 17:00 Plenary Symposium 6

PS6 Developmental Biology of Pigment Cells

KL13 From the Neural Crest to the Pigment Cells
Nicole M. Le Douarin

15:00 - 17:00 Public Forum
Wonder of Animal Colors
Hiroshi Hori, P. Bernhardt Koch, James J. Nordlund

17:00 - 18:30 Poster Prizes and Farewell Drink (at the NCC)

6th Day, Thursday, November 4, 1999

09:00 -17:00 Satellite Meeting 3
SM3 Cellular and Molecular Control of Pigment Cell Development
Organizers: Dorothy C. Bennett, Randolph Morrison, Shin-Ichi Nishikawa

09:00 - 13:00 Satellite Meeting 4
SM4 Sentinel Node Mapping and Dissection in Diagnosis and Treatment of Melanoma
Organizers: Alistair J. Cochran and Toshiaki Saida

Update for the IXth Annual Meeting of the PASPCR

by Lynn Lamoreux

We had our telephone Council meeting today. Remarkable, talking all at once to New Haven, Minneapolis, Bryan/College Station. This is almost as fascinating as the concept of flying across the international date line, and always puts me in a philosophical mood.

Hmmm.

Bryan/College Station.

Here I am now In Bryan (currently in the final cut for All American City), in the fastest growing county of the fastest growing state, the place where former presidents come to raise up their sons to be future presidents. Our newest member of NAS (we have several - also Nobel Prize winners, President of AMA, etc., etc.) asked me yesterday: "Would you want to live anywhere else?"

I guess not. Been there; done that. I'm driving home (it's about 14 miles, none of which is in the city). Above, cloud-shadow rays of the setting sun streak across the clearest of skies, soft, the colors of pinkeyed mice and himalayan mice, meeting the rising moon. It's perfect shirt-sleeve weather. No need to put anything on; no need to take anything off. Invisible under the wheels lies one of the richest oil fields in the world. But is it richer than the masses of golden Texas sunflowers that border the road? Or my neighbor's brindle F1 heifers (the gene is carried by the hereford mother), or his corn waving in the field beyond that I cannot see over even from horesback? I don't think so. Without these riches there would be no Bethesda or no Cincinnati, and California would probably drop off the edge as threatened.

When I get home I pen the ewes (the colors of black, brown and Sl/Sl^P or Mi^{OR}/mi^B mice) to check for impending births and it occurs to me that -- without Dolly and her multitude of amphibian and murine relatives --

there would be no cloning. Without biological systems there would be no point to molecular biology. It would, in fact, not be biology. And without biological controls to confirm *in vitro* results, molecular biology would still be tottering along in its descriptive stages instead of transmuting the physiological genetics of my major professor -- OK, me too -- into the physiological genomics of tomorrow's professors. (That, by the way is one of the subjects to be covered at our next PASPCR meeting. And those yellow mice were right in there the whole way!). Because we at TAMU have two (at least) of the best resources that exist in terms of animal models, and because our institution is somewhere near the top ten nationally in funding for basic, medical and veterinary research, we want our next meeting to address these riches and the ways in which they enable worldwide advances in biochemistry, cell biology and molecular biology and medicine.

And without the opportunity for cooperation toward a goal, there would be no point to competition. That's why PASPCR is our favorite organization, and that's the theme for the ninth annual meeting to be held in College Station, Texas during June 25-28, 2000.

If anyone can think of a shorter way to say it, please let me know.

Topics to be covered at the meeting will include:

Vertebrate Genetics and Pigmentation (that includes people) with invited speakers including Shin-Ichi Nishikawa, Greg Barsh, Roger Cone and George Wolff.

Making sense of MITF: its multiple roles in human and mouse disorders, with invited speakers including Shigeki Shibahara and Colin Goding.

Melanoma: New genes, gene therapy and animal models with invited speakers including Osvaldo Podhajcer, Menashe Bar-Eli and Max Amoss.

Melanosome Genesis, Function and Transfer to Keratinocytes, with invited speakers including Ray Boissy and Miri Seiberg

Signal Transduction, UV Irradiation and Pigmentation, with invited speakers including Hee-Young Park

Don't forget Vince Hearing!

You can see we will be plenty busy with meeting, but if you can stand the heat, bring the kids. This is a family-friendly community with lots of friendly activities for everyone.

Lynn

Positions - Wanted and Available :

Postdoctoral Positions. in the Department of Cell Biology at the NYU School of Medicine are available to study the biogenesis of melanosomes using a combined cellular, molecular and genetic approach. Prior experience in molecular or cell biology required. Applications from those with prior experience with yeast, *Drosophila* etc. interested in applying their skills to a mammalian system with strong genetics are especially welcome. A track record of productivity is essential. Send CV, brief description of experience and names of 3

references to: Seth J. Orlow, MD, PhD, NYU Medical Center, 560 First Avenue Room H-100, New York, NY 10016. Fax 212-263-5819, email: orlows01@mccr.med.nyu.edu

Postdoctoral Research Associate - Position available to study the biology of human inherited disorders of pigmentation using mouse knockout technology. The successful applicant will have a Ph.D. and/or M.D. with experience in cell biology and molecular biology. Experience with production of knockout mice using ES cell technology preferred. Please send curriculum vitae along with the names of three references to Dr. Richard King, Division of Genetics, Department of Medicine, Box 485 Mayo, 420 Delaware St. S.E., University of Minnesota, Minneapolis, MN 55455. Equal Opportunity Employer.

Postdoctoral Position - Ph.D. in molecular biology, biophysics, genetics or biochemistry. Position available to conduct research on molecular mechanisms of cellular response to oxidative stress in human melanocytes and melanoma cells and its regulation for preventive and therapeutic indications. Contact Dr. Frank L. Meyskens Jr., Director, University of California-Irvine, Chao Family Clinical Cancer Research Center, 101 The City Drive, Orange, CA 92668, USA. Fax (714) 456-5039 Email flmeyske@uci.edu

Members in the News -

Seymour Pomerantz - is retiring and going to Israel. We will miss his presence, but fortunately, not his valuable antibodies. As part of his contribution to aid in future pigment cell research, he has sent all his antibodies to Ruth Halaban for distribution. As part of this lot, Dr. Pomerantz has left several tubes containing anti-MSH rabbit serum. Ruth would like someone in the society to store these antibodies and distribute them to interested investigators. If you are interested in helping in the utilization of this valuable resource, please contact Dr. Ruth Halaban.

Ray Boissey - has retired as the Treasure of the PASPCR and this position will be taken up once again by Jim Nordlund. We would like to thank Ray for his help in taking up this important task.

Bibliography :

The Bibliography published in this issue covers the period February, 1999 through April, 1999. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. By its very nature, assignment of a reference to a particular category may be arbitrary and we urge you to read through all categories to make sure you don't miss any pertinent to your field. We have attempted to highlight any publications which include a member of the PASPCR with a star (*sorry if we missed you but let us know and you'll get a free marked repeat in the next issue*).

MELANINS, MELANOGENS & MELANOGENESIS

- Berreau LM, Mahapatra S, Halfen JA, Houser RP, Young VG, Tolman WB: Reactivity of peroxo- and bis(Mu-oxo)dicopper complexes with catechols. *Angew.Chem.Int.Ed* 38:207-210 (1999).
- Bicamumpaka C, Page M: Paclitaxel stimulates melanogenesis in B16-F1 melanoma cells. *Anticancer Res.* 18:4101-4104 (1998).
- Borovansky J, Hach P, Smetana K, Elleder M, Matous-Malbohan I: Attempts to induce melanosome degradation *in vivo*. *FOLIA BIOL.PRAGUE.* 45:47-52 (1999).
- Butler MJ, Day AW: Fungal melanins: a review. *CAN.J.MICROBIOL.* 44:1115-1136 (1998).
- Daquinag AC, Sato T, Koda H, Takao T, Fukuda M, Shimonishi Y, Tsukamoto T: A novel endogenous inhibitor of phenoloxidase from *Musca domestica* has a cystine motif commonly found in snail and spider toxins. *BIOCHEMISTRY USA* 38:2179-2188 (1999).
- Drago F, Marino A, LaManna C: α -methyl-p-tyrosine inhibits latanoprost-induced melanogenesis *in vitro*. *Exp.Eye Res.* 68:85-90 (1999).
- Espin JC, Jolivet S, Overeem A, Wichers HJ: Agaritine from *Agaricus bisporus* is capable of preventing melanin formation. *Phytochemistry* 50:555-563 (1999).
- Hardie RJ: Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [F-18] dopa PET. *J.Neurol.Neurosurg.Psychiat.* 66:256 (1999).
- Ilija M, Jeffery G: Retinal mitosis is regulated by dopa, a melanin precursor that may influence the time at which cells exit the cell cycle: Analysis of patterns of cell production in pigmented and albino retinæ. *J.COMP NEUROL.* 405:394-405 (1999).

- Kikuchi J, Asakura T, Loach PA, Parkes-Loach PS, Shimada K, Hunter CN, Conroy MJ, Williamson MP: A light-harvesting antenna protein retains its folded conformation in the absence of protein-lipid and protein-pigment interactions. *Biopolymers* 49:361-372 (1999).
- Leblanc B, Jezequel S, Davies T, Hanton G, Taradach C: Binding of drugs to eye melanin is not predictive of ocular toxicity. *REGUL.TOXICOL.PHARMACOL.* 28:124-132 (1998).
- Mishima K, Amemiya T, Takano K: X-ray microanalysis of melanin granules of retinal pigment epithelium and choroid in hereditary copper deficient mice (Macular mice). *Exp.Eye Res.* 68:59-65 (1999).
- Miyamae T, Goshima Y, Shimizu M, Shibata T, Kawashima K, Ohshima E, Suzuki F, Mitsu Y: Some interactions of L-DOPA and its related compounds with glutamate receptors. *Life Sci.* 64:1045-1054 (1999).
- Offen D, Gorodin S, Melamed E, Hanania J, Malik Z: Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. *Neurosci.Lett.* 260:101-104 (1999).
- Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R: Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. *NEUROREPORT* 10:557-561 (1999).
- Price K, Linge C: The presence of melanin in genomic DNA isolated from pigmented cell lines interferes with successful polymerase chain reaction: a solution. *Melanoma Res.* 9:5-9 (1999).
- Rożanowska M, Sarna T, Land EJ, Truscott TG: Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. *FREE RADICAL BIOL.MED.* 26:518-525 (1999).
- Shimizu K, Tanaka C, Peng YL, Tsuda M: Phylogeny of *Bipolaris* inferred from nucleotide sequences of *Brn1*, a reductase gene involved in melanin biosynthesis. *J.Gen.Appl.Microbiol.* Tokyo 44:251-258 (1998).
- *Singh MV, Jimbow K: Tyrosinase transfection produces melanin synthesis and growth retardation in glioma cells. *Melanoma Res.* 8:493-498 (1998).
- Wrobel D, Hanyz I, Planner A, Dudkowiak A, Sarna T: Energy deactivation pathways of porphyrins and dopa melanin in polyvinyl alcohol systems. *J.PHOTOCHEM.PHOTOBIOL.B BIOL.* 47:165-172 (1998).
- Zou LL, Jankovic J, Rowe DB, Xie WJ, Appel SH, Le WD: Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. *Life Sci.* 64:1275-1285 (1999).
- Zughaier SM, Ryley HC, Jackson SK: A melanin pigment purified from an epidemic strain of *Burkholderia cepacia* attenuates monocyte respiratory burst activity by scavenging superoxide anion. *Infect.Immunity.* 67:908-913 (1999).

MELANOCYTES & KERATINOCYTES

- AbdelNaser MB: Differential effects on melanocyte growth and melanization of low vs. high calcium keratinocyte-conditioned medium. *Brit.J.Dermatol.* 140:50-55 (1999).
- *Bagnara JT: The emergence of pigment cell biology: A personal view. *Pigm.Cell Res.* 12:48-65 (1999).
- Ballone E, Passamonti M, Lappa G, Di Blasio G, Fazii P: Pigmentary traits, nevi and skin phototypes in a youth population of central Italy. *EUR.J.EPIDEMIOL.* 15:189-195 (1999).
- Basarac T, Picard JK, Simpson E, RussellJones R: Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas. *Brit.J.Dermatol.* 140:106-108 (1999).
- Blessing K: Benign atypical naevi: diagnostic difficulties and continued controversy. *Histopathology* 34:189-198 (1999).
- Brown DA, Lesiak K, Ren WY, Strzelecki KL, Khorlin AA: Bicyclic monoterpene diols induce differentiation of S91 melanoma and PC12 pheochromocytoma cells by a cyclic guanosine-monophosphate-dependent pathway. *Pigm.Cell Res.* 12:36-47 (1999).
- Buchdahl C, Papon J, Communal Y, Bourges M, Madelmont JC: G(2) accumulation and melanin overproduction in malignant melanocytes treated with a new nitrosourea. *Melanoma Res.* 8:517-527 (1998).
- Busam KJ: Metastatic melanoma to the skin simulating blue nevus. *Amer.J.Surg.Pathol.* 23:276-282 (1999).
- Carli P, Massi D, Santucci M, Biggeri A, Giannotti B: Cutaneous melanoma histologically associated with a nevus and melanoma *de novo* have a different profile of risk: Results from a case-control study. *J.Amer.Acad.Dermatol.* 40:549-557 (1999).
- Cloudsley-Thompson JL: Multiple factors in the evolution of animal coloration. *NATURWISSENSCHAFTEN* 86:123-132 (1999).
- *Curto EV, Kwong C, Hermersdorfer H, Glatt H, Santis C, Virador V, Hearing VJ, Dooley TP: Inhibitors of mammalian melanocyte tyrosinase: *In vitro* comparisons of alkyl esters of gentisic acid with other putative inhibitors. *Biochem.Pharmacol.* 57:663-672 (1999).
- Eves P, Smith-Thomas L, Hedley S, Wagner M, Balafa C, MacNeil S: A comparative study of the effect of pigment on drug toxicity in human choroidal melanocytes and retinal pigment epithelial cells. *Pigm.Cell Res.* 12:22-35 (1999).
- Farinas-Alvarez C, Rodenas JM, Herranz MT, Delgado-Rodriguez M: The naevus count on the arms as a predictor of the number of melanocytic naevi on the whole body. *Brit.J.Dermatol.* 140:457-462 (1999).
- Ferrer C, Solano F, Zuasti A: Ultrastructural and biochemical analysis of epidermal xanthophores and dermal chromatophores of the teleost *Sparus aurata*. *Histol.Histopathol.* 14:383-390 (1999).
- Firooz A, Komeili A, Dowlati Y: Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas. *J.Amer.Acad.Dermatol.* 40:646-647 (1999).
- Glaessel A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W: Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. *Arch.Dermatol.Res.* 291:81-87 (1999).
- Harrison SL, Buettner PG, MacLennan R: Body-site distribution of melanocytic nevi in young Australian children. *Arch.Dermatol.* 135:47-52 (1999).
- Ho N, Roig C, Diadori P: Epidermal nevi and localized cranial defects. *Amer.J.Med.Genet.* 83:187-190 (1999).
- Iyengar B: The UV-Responsive melanocyte system: A peripheral network for photoperiodic time measurements - A function of indoleamine expression. *Acta Anat.* 163:173-178 (1998).
- *Jin EJ, Thibaudeau G: Effects of lithium on pigmentation in the embryonic zebrafish (*Brachydanio rerio*). *Bba.Mol.Cell Res.* 1449:93-99 (1999).

- Kemp EH, Ajjan RA, Waterman EA, Gawkrödger DJ, Cork MJ, Watson PF, Weetman AP: Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo. *Brit.J.Dermatol.* 140:73-78 (1999).
- *Kos L, Aronzon A, Takayama H, Maina F, Ponzetto C, Merlino G, Pavan W: Hepatocyte growth factor scatter factor MET signaling in neural crest-derived melanocyte development. *Pigm.Cell Res.* 12:13-21 (1999).
- *Le Poole IC, Boyce ST: Keratinocytes suppress transforming growth factor- β 1 expression by fibroblasts in cultured skin in substitutes. *Brit.J.Dermatol.* 140:409-416 (1999).
- Lee HS, Chun YS, Hann SK: Nevus depigmentosus: Clinical features and histopathologic characteristics in 67 patients. *J.Amer.Acad.Dermatol.* 40:21-26 (1999).
- LockAndersen J, Drzewiecki KT, Wulf HC: Eye and hair colour, skin type and constitutive skin pigmentation as risk factors for basal cell carcinoma and cutaneous malignant melanoma - A Danish case-control study. *Acta Dermato.Venereol.* 79:74-80 (1999).
- Maeda K, Naganuma M: Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. *J.PHOTOCHEM.PHOTOBIOLOG.BIOL.* 47:136-141 (1998).
- Maeda T, Eller MS, Hedayati M, Grossman L, Gilchrest BA: Enhanced repair of benzo(a)pyrene-induced DNA damage in human cells treated with thymidine dinucleotides. *Mutat.Res.DNA Repair* 433:137-145 (1999).
- Marklund S, Moller M, Sandberg K, Andersson L: Close association between sequence polymorphism in the KIT gene and the roan coat color in horses. *Mamm.Genome* 10:283-288 (1999).
- Massi D, Carli P, Franchi A, Santucci M: Naevus-associated melanomas: cause or chance? *Melanoma Res.* 9:85-91 (1999).
- Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE: A 12 month, randomized, double masked study comparing latanoprost with timolol in pigmentary glaucoma. *OPHTHALMOLOGY* 106:550-555 (1999).
- McGregor B, Pfitzner J, Zhu G, Grace M, Eldridge A, Pearson J, Mayne C, Aitken JF, Green AC, Martin NG: Genetic and environmental contributions to size, color, shape, and other characteristics of melanocytic naevi in a sample of adolescent twins. *Genet.Epidemiol.* 16:40-53 (1999).
- *Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M: Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. *Int.J.Cancer* 84:160-168 (1999).
- Musette P, Bachelez H, Flageul B, Delarbre C, Kourilsky P, Dubertret L, Gachelin G: Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. *J.Immunol.* 162:1789-1794 (1999).
- Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, Takahashi K, Kure S, Hara M, Kanegae Y, Saito I, Narisawa K: Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. *PEDIAT.RES.* 45:465-473 (1999).
- Nawa Y, Hara Y, Saishin M: Conjunctival melanoma associated with extensive congenital conjunctival nevus and split nevus of eyelid. *Arch.Ophthalmol.* 117:269-271 (1999).
- Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. *Proc.Nat.Acad.Sci.Usa* 96:2982-2987 (1999).
- Ozer E, Sagol O, Kuyucuoglu F: Ki-67 immunostaining and stereologic estimation of nuclear volume in melanocytic skin tumors. *Anal.Quant.Cytol.Histol.* 21:42-46 (1999).
- Pedley J, Pettit A, Parsons PG: Inhibition of Ku autoantigen binding activity to the E2F motif after ultraviolet B irradiation of melanocytic cells. *Melanoma Res.* 8:471-481 (1998).
- Portnoi MF, Boutchnei S, Bouscarat F, Morlier G, Nizard S, Dersarkissian H, Crickx B, Nouchy M, Taillemite JL, Belaich S: Skin pigmentary anomalies and mosaicism for an acentric marker chromosome originating from 3q. *J.Med.Genet.* 36:246-250 (1999).
- *Potterf SB, Virador V, Wakamatsu K, Furumura M, Santis C, Ito S, Hearing VJ: Cysteine transport in melanosomes from murine melanocytes. *Pigm.Cell Res.* 12:4-12 (1999).
- Rathinam SR, Namperumalsamy P, Nozik RA, Cunningham ET: Vogt-Koyanagi-Harada syndrome after cutaneous injury. *OPHTHALMOLOGY* 106:635-638 (1999).
- Reeck MC, Chuang TY, Eads TJ, Faust HB, Farmer ER, Hood AE: The diagnostic yield in submitting nevi for histologic examination. *J.Amer.Acad.Dermatol.* 40:567-571 (1999).
- Rees JL, Flanagan N: Pigmentation, melanocortins and red hair. *QJM.MON.J.ASSOC.PHYSICIAN* 92:125-131 (1999).
- Robinson WA, Lemon M, Elefanty A, HarrisonSmith M, Markham N, Norris D: Human acquired naevi are clonal. *Melanoma Res.* 8:499-503 (1998).
- Schempp CM, Muller K, Schulte-Monting J, Schopf E, Simon JC: Salt water bathing prior to UVB irradiation leads to a decrease of the minimal erythema dose and an increased erythema index without affecting skin pigmentation. *Photochem.Photobiol.* 69:341-344 (1999).
- Schraermeyer U, Peters S, Thumann G, Kociok N, Heimann K: Melanin granules of retinal pigment epithelium are connected with the lysosomal degradation pathway. *Exp.Eye Res.* 68:237-245 (1999).
- Shuster SM, Levy L: Sex-linked inheritance of a cuticular pigmentation marker in the marine isopod, *Paracerceis sculpta* Holmes (Crustacea: Isopoda: Sphaeromatidae). *J.Hered.* 90:304-307 (1999).
- Signoretti S, Annessi G, Puddu P, Faraggiana T: Melanocytic nevi of palms and soles - A histological study according to the plane of section. *Amer.J.Surg.Pathol.* 23:283-287 (1999).
- Smith HB: Photosynthetic pigmentation - Variations on a theme. *Plant Cell* 11:1-3 (1999).
- StamPosthuma JJ, Vink J, leCessie S, Bruijn JA, Bergman W, Pavel S: Effect of topical tretinoin under occlusion on atypical naevi. *Melanoma Res.* 8:539-548 (1998).
- Welsh BM, Mason RS, Halliday GM: Topical all-trans retinoic acid augments ultraviolet radiation-induced increases in activated melanocyte numbers in mice. *J.INVEST DERMATOL.* 112:271-278 (1999).
- Wu XF, Bowers B, Rao K, Wei Q, Hammer JA: Visualization of melanosome dynamics within wild-type and dilute melanocytes suggests a paradigm for myosin V function *in vivo*. *J.Cell Biol.* 143:1899-1918 (1998).

MELANOMA & METASTASIS

- Blood test for melanoma antigen. *Eur.J.Cancer* 35:167-167 (1999).
- Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N: CDKN2A variants in a population-based sample of queensland families with melanoma. *J.Nat.Cancer Inst.* 91:446-452 (1999).
- Alexander CL, Edward M, MacKie RM: Pentoxifylline-induced modulation of melanoma cell growth, adhesion and lymphokine activated killer cell-mediated lysis. *Melanoma Res.* 9:31-39 (1999).
- Andersson HC, Lewensohn R, Mansson-Brahme E: Chromosomal sensitivity to X-ray irradiation during the G(2) phase in lymphocytes of patients with hereditary cutaneous malignant melanoma as compared to healthy controls. *Mutat.Res.Fundam.Mol.Mech.Mut.* 425:9-20 (1999).
- Argenziano G, Fabbrocini G, Carli P, DeGiorgi V, Delfino M: Clinical and dermatoscopic criteria for the preoperative evaluation of cutaneous melanoma thickness. *J.Amer.Acad.Dermatol.* 40:61-68 (1999).
- Asai M, Kato M, Asai N, Iwashita T, Murakami H, Kawai K, Nakashima I, Takahashi M: Differential regulation of MMP-9 and TIMP-2 expression in malignant melanoma developed in Metallothionein/RET transgenic mice. *Jpn.J.Cancer Res.* 90:86-92 (1999).
- Ascierto PA, Satriano PA, Palmieri G, Parasole R, Bosco L, Castello G: Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. *Melanoma Res.* 8:529-537 (1998).
- Ascierto PA, Palmieri G, Parasole R, Daponte A, Castello G: 3-year treatment with recombinant interferon- α as adjuvant therapy of cutaneous malignant melanoma. *Int.J.Mol.Med.* 3:303-306 (1999).
- Ascierto PA, Palmieri G: Adjuvant therapy of cutaneous melanoma. *Lancet* 353:328 (1999).
- Balazs M, Adam Z, Begany A, Takruri AT, Adany R: Involvement of chromosome losses in the progression and metastasis formation of a human malignant melanoma. *Cancer Genet.Cytogenet.* 109:114-118 (1999).
- Banfield CC, Dawber RPR, Walker NPJ, Stables GI, Zeina B, Schomberg K: Mohs micrographic surgery for the treatment of *in situ* nail apparatus melanoma: A case report. *J.Amer.Acad.Dermatol.* 40:98-99 (1999).
- Barbosa AD, Guimaraes NS, Lopes MD, Sadigursky M, Bittencourt M: Malignant melanoma and basal cell carcinoma in a combined tumour. *Brit.J.Dermatol.* 140:360-361 (1999).
- BarEli M: Role of interleukin-8 in tumor growth and metastasis of human melanoma. *Pathobiology* 67:12-18 (1999).
- Bataille V, Sasieni P, Curley RK, Cook MG, Marsden RA: Melanoma yield, number of biopsies and missed melanomas in a British teaching hospital pigmented lesion clinic: a 9- year retrospective study. *Brit.J.Dermatol.* 140:243-248 (1999).
- Batlwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. *MOL.MED.* 4:783-794 (1998).
- *Birkle S, Ren SL, Slominski A, Zeng GC, Gao LY, Yu RK: Down-regulation of the expression of O-acetyl-GD3 by the O-acetyltransferase cDNA in hamster melanoma cells: Effects on cellular proliferation, differentiation, and melanogenesis. *J.Neurochem.* 72:954-961 (1999).
- Bleyen L, De Bacquer D, Myny K, Brochez L, Naeyaert JM, De Backer G: Trends in mortality from cutaneous malignant melanoma in Belgium. *Int.J.Epidemiol.* 28:40-45 (1999).
- Blumenthal EZ, Peer J: Multifocal choroidal malignant melanoma: At least 3 melanomas in one eye. *Arch.Ophthalmol.* 117:255-258 (1999).
- Bongers V, Rinkes IHMB, Barneveld PC, CanningavanDijk MR, vanRijk PP, vanVloten WA: Towards quality assurance of the sentinel node procedure in malignant melanoma patients: a single institution evaluation and a European survey. *Eur.J.Nucl.Med.* 26:84-90 (1999).
- Bono A, Tomatis S, Bartoli C, Tragni G, Radaelli G, Maurichi A, Marchesini R: The ABCD system of melanoma detection - A spectrophotometric analysis of the asymmetry, border, color, and dimension. *Cancer* 85:72-77 (1999).
- Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R: *In situ* expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. *J.Pathol.* 187:446-454 (1999).
- Bostick P, Essner R, Glass E, Kelley M, Sarantou T, Foshag LJ, Qi K, Morton D: Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. *Arch.Surg.* 134:43-49 (1999).
- Bullock GJ, Green JL, Baron PL: Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma. *AMER.J.SURG.* 177:15-18 (1999).
- Buseti A, Soncin M, Jori G, Rodgers MAJ: High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. *Brit.J.Cancer* 79:821-824 (1999).
- Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R: Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. *Melanoma Res.* 8:549-556 (1998).
- Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G: Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. *J.Immunol.* 162:1739-1748 (1999).
- Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW: Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma - A case report and review of the literature. *Cancer* 85:1055-1059 (1999).
- Chan MC, Murphy RM: Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high- molecular-weight melanoma-associated antigen. *Cancer Immunol.Immunother.* 47:321-329 (1999).
- Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, Foss AJE, Hungerford JL: c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. *Brit.J.Ophthalmol.* 83:110-114 (1999).
- Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP: Human melanoma cells do not express Fas (Apo-1/CD95) ligand. *Cancer Res.* 59:59-62 (1999).

- Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, Wunderlich J, Rosenberg SA, Nishimura MI: Changes in the fine specificity of gp100((209-217))- reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. *J.Immunol.* 162:1749-1755 (1999).
- Cochlovius B, Perschl A, Adema GJ, Zoller M: Human melanoma therapy in the SCID mouse: *In vivo* targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments. *Int.J.Cancer* 81:486-493 (1999).
- Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M: Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). *J.Immunother.* 22:16-24 (1999).
- Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM: Natural variation of the expression of HLA and endogenous antigen modulates ctl recognition in an *in vitro* melanoma model. *Int.J.Cancer* 80:781-790 (1999).
- Danielsson C, Torma H, Vahlquist A, Carlberg C: Positive and negative interaction of 1,25-dihydroxyvitamin D-3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. *Int.J.Cancer* 81:467-470 (1999).
- Degen WGJ, Agterbos MA, Muylers JPP, Bloemers HPJ, Swart GWM: memA/DRS, a putative mediator of multiprotein complexes, is overexpressed in the metastasizing human melanoma cell lines BLM and MV3. *BBA.GENE STRUCT.EXPRESS* 1444:384-394 (1999).
- Delbeke D: Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer lymphoma and melanoma. *J.Nucl.Med.* 40:591-603 (1999).
- Demerais F, Chompret A, Briollais L, De Paillerets BB, Avril MF: Hereditary predisposition to malignant skin melanoma and gene-environment interactions. *EUROCANCER*.98. 111-112:-112 (1998).
- Demir G, Demirelli F, Ozguroglu M, MolinasMandel N, Buyukunal E, Tuzuner N, Serdengeci S, Berkarda B: Immune effects of low-dose subcutaneous interleukin-2 in patients with metastatic malignant melanoma. *Int.J.Immunother.* 14:163-168 (1998).
- Diaz CE, Rusciano D, Dithmar S, Grossniklaus HE: B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC). *Curr.Eye Res.* 18:125-129 (1999).
- Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, Hunter JAA: A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. *Brit.J.Dermatol.* 140:249-254 (1999).
- Dieckmann K, Zehetmayer M, Poetter R: Fractionated stereotactic radiotherapy for choroidal melanoma. *Radiother.Oncol.* 49:197 (1998).
- Dong XD, DeMatos P, Prieto VG, Seigler HF: Melanoma of the gallbladder - A review of cases seen at Duke University Medical Center. *Cancer* 85:32-39 (1999).
- Dorval T, Negrier S, Chevreau C, Avril MF, Baume D, Cupissol D, Oskam R, de Peuter R, Vinke J, Herrera L, Escudier B: Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon- α -2a in patients with metastatic melanoma. *Cancer* 85:1060-1066 (1999).
- Dressel R, Johnson JP, Gunther E: Heterogeneous patterns of constitutive and heat shock induced expression of HLA-linked HSP70-1 and HSP70-2 heat shock genes in human melanoma cell lines. *Melanoma Res.* 8:482-492 (1998).
- Earle JD: Results from the collaborative ocular melanoma study (COMS) of enucleation versus preoperative radiation therapy in the management of large ocular melanomas. *Int.J.Radiat.Oncol.Biol.Phys.* 43:1168-1169 (1999).
- Epstein DS, Lange JR, Gruber SB, Mofid M, Koch SE: Is physician detection associated with thinner melanomas? *Jama J.Am.Med.Assn.* 281:640-643 (1999).
- Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T: Screening for metastatic malignant melanoma of the uvea revisited. *Cancer* 85:1151-1159 (1999).
- Fan Q, Feng ZH, Zhang GM, Zhang H, Cao HQ: Effect of recombinant human fibronectin polypeptide CH50 on growth and metastasis of melanoma. *Acta Pharmacol.Sin.* 20:175-178 (1999).
- Fetsch PA, Marincola FM, Filie A, Hijazi YM, Kleiner DE, Abati A: Melanoma-associated antigen recognized by T cells (MART-1) - The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. *Cancer Cytopathol.* 87:37-42 (1999).
- Finger PT, Berson A, Szechter A: Palladium-103 plaque radiotherapy for choroidal melanoma - Results of a 7-year study. *OPHTHALMOLOGY* 106:606-613 (1999).
- Fisher SR: Considerations in the surgical treatment of malignant melanoma. *Arch.Otolaryngol.Head Neck Surgery* 125:116-117 (1999).
- Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS: Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma. *Oncogene* 18:1023-1032 (1999).
- Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fossier V, Tonato M, Carlini P, Boni C, Di Sarra S: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma A prospective study. *Cancer* 85:1599-1605 (1999).
- Fu YM, Yu ZX, Pelayo BA, Ferrans VJ, Meadows GG: Focal adhesion kinase-dependent apoptosis of melanoma induced by tyrosine and phenylalanine deficiency. *Cancer Res.* 59:758-765 (1999).
- Fujiwara Y, Chi DDJ, Wang HJ, Keleman P, Morton DL, Turner R, Hoon DSB: Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. *Cancer Res.* 59:1567-1571 (1999).
- *Fukuda H, Honda C, Wadabayashi N, Kobayashi T, Yoshino K, Hiratsuka J, Takahashi J, Akaizawa T, Abe Y, Ichihashi M, Mishima Y: Pharmacokinetics of B-10-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. *Melanoma Res.* 9:75-83 (1999).
- Geiser M, Schultz D, LeCardinal A, Voshol H, GarciaEcheverria C: Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. *Cancer Res.* 59:905-910 (1999).
- Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. *J.Clin.Oncol.* 17:976-983 (1999).

- Gibbs P, Cebon JS, Calafiore P, Robinson WA: Cardiac metastases from malignant melanoma. *Cancer* 85:78-84 (1999).
- Godden JL, Edward M, MacKie RM: Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis - The role of platelet-derived growth factor. *Eur.J.Cancer* 35:473-480 (1999).
- Gogel BM: Sentinel lymph node biopsy for melanoma - Closing. *AMER.J.SURG.* 176:547 (1998).
- Gogel BM, Kuhn JA, Ferry KM, Fisher TL, Preskitt JT, OBrien JC, Lieberman ZH, Stephens JS, Krag DN: Sentinel lymph node biopsy for melanoma. *AMER.J.SURG.* 176:544-547 (1998).
- Goldmann T, Suter L, Ribbert D, Otto F: The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis. *Pathol.Res.Pract.* 195:171-175 (1999).
- Grant-Kels JM, Bason ET, Grin CM: The misdiagnosis of malignant melanoma. *J.Amer.Acad.Dermatol.* 40:539-548 (1999).
- Griffioen M, Ouwerkerk IJM, Harten V, Schrier PI: HLA-B down-regulation in human melanoma is mediated by sequences located downstream of the transcription- initiation site. *Int.J.Cancer* 80:573-580 (1999).
- Griffioen M, Ouwerkerk IJM, Harten V, Gobin SJP, van den Elsen PJ, Schrier PI: Role of the interferon-stimulated response element in HLA- B downregulation in human melanoma cell lines. *Immunogenetics* 49:287-294 (1999).
- Gude RP, Binda MM, Presas HL, Klein-Szanto AJP, Bonfil RD: Studies on the mechanisms responsible for inhibition of experimental metastasis of B16-F10 murine melanoma by pentoxifylline. *J.BIOMED.SCI.* 6:133-141 (1999).
- Guldberg P, Straten PT, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J: Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. *Oncogene* 18:1777-1780 (1999).
- Gunduz K, Shields CL, Shields JA, Cater J, Freier JE, Brady LW: Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. *Arch.Ophthalmol.* 117:170-177 (1999).
- Gutbrod H, Scharfl M: Intragenic sex-chromosomal crossovers of Xmrk oncogene alleles affect pigment pattern formation and the severity of melanoma in xiphophorus. *Genetics* 151:773-783 (1999).
- Haapajarvi T, Pitkanen K, Laiho M: Human melanoma cell line UV responses show independency of p53 function. *Cell Growth Differ.* 10:163-171 (1999).
- Hadzantonis M, ONeill H: Dendritic cell immunotherapy for melanoma. *Cancer Biother.Radiopharm.* 14:11-22 (1999).
- Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L: Expression of ICAM-1 during IFN- α -based treatment of metastatic malignant melanoma: Relation to tumor- infiltrating mononuclear cells and regressive tumor changes. *J.INTERFERON CYTOKINE RES.* 19:171-177 (1999).
- Hall HI, Miller DR, Rogers JD, Bewerse B: Update on the incidence and mortality from melanoma in the United States. *J.Amer.Acad.Dermatol.* 40:35-42 (1999).
- Hamaker RC: Experience and clinical judgment required in the treatment of malignant melanoma. *Arch.Otolar.Head Neck Surgery* 125:115-116 (1999).
- Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, Klein CE : Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. *Cancer Res.* 59:1578-1583 (1999).
- Hashemi J, Linder S, Platz A, Hansson J: Melanoma development in relation to nonfunctional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. *Melanoma Res.* 9:21-30 (1999).
- Hemo Y, Gutman M, Klausner JM: Anatomic site of primary melanoma is associated with depth of invasion. *Arch.Surg.* 134:148-150 (1999).
- Hernberg M, Pyrhonen S, Muhonen T: Regimens with or without interferon- α as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials. *J.Immunother.* 22:145-154 (1999).
- Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, DasGupta TK: Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. *Cancer* 85:375-382 (1999).
- Hofmann B, Fischer CO, Lawaczek R, Platzek J, Semmler W: Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent gadobutrol. *Invest Radiol.* 34:126-133 (1999).
- Hsueh EC, Lucci A, Qi K, Morton DL: Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. *Cancer* 85:383-388 (1999).
- Junghans V, Runger TM: Hypertriglyceridaemia following adjuvant interferon- α treatment in two patients with malignant melanoma. *Brit.J.Dermatol.* 140:183-184 (1999).
- Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma - Association with disease progression. *AMER.J.PATHOL.* 154:745-754 (1999).
- Kageshita T, Matsui T, Hirai S, Fukuda Y, Ono T: Hypercalcaemia in melanoma patients associated with increased levels of parathyroid hormone-related protein. *Melanoma Res.* 9:69-73 (1999).
- Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM, Kosma VM: p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. *Brit.J.Cancer* 79:895-902 (1999).
- Kawada M, Amemiya M, Ishizuka M, Takeuchi T: Differential induction of apoptosis in B16 melanoma and EL- 4 lymphoma cells by cytostatin and bactobolin. *Jpn.J.Cancer Res.* 90:219-225 (1999).
- Kemeny MM, Stewart AK: Superior survival of young women with malignant melanoma - The reply. *AMER.J.SURG.* 177:176-176 (1999).
- Kiehl P, Matthies B, Ehrlich K, Volker B, Kapp A: Accuracy of frozen section measurements for the determination of Breslow tumour thickness in primary malignant melanoma. *Histopathology* 34:257-261 (1999).
- Kim CJ, Chan CC, Rosenberg SA: Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens. *J.Immunother.* 22:182-183 (1999).
- Kim SH, Garcia C, Rodriguez J, Coit DG: Prognosis of thick cutaneous melanoma. *J.Amer.Coll.Surgeons.* 188:241-247 (1999).
- *Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL, Edington HD, Donnelly SS, Becker D: Systemic interferon- α (IFN- α) treatment leads to Stat3 inactivation in melanoma precursor lesions. *MOL.MED.* 5:11-20 (1999).
- Kittlesen DJ, Thompson LW, Gulden PH, Skipper JCA, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL: Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (Vol 160, pg 2099, 1998). *J.Immunol.* 162:3106 (1999).
- Koch SE, Henneberry JM: Clinically subtle primary cutaneous melanoma. *J.Amer.Acad.Dermatol.* 40:252-254 (1999).

- Komori H, Ichikawa S, Hirabayashi Y, Ito M: Regulation of intracellular ceramide content in B16 melanoma cells - Biological implications of ceramide glycosylation. *J.Biol.Chem.* 274:8981-8987 (1999).
- Kozłowska K, Cichorek M, Zarzeczna M: Estimation of oncostatin M (OSM) secretion by peritoneal macrophages with regard to the progression of transplantable melanomas. *NEOPLASMA* 45:369-372 (1998).
- Kozłowska K, Nowak J, Kwiatkowski B, Cichorek M: ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. *Exp.Toxicol.Pathol.* 51:89-92 (1999).
- Kramer DL, Vujcic S, Diegelman P, White C, Black JD, Porter CW: Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. *Biochem.Soc.Trans.* 26:609-614 (1998).
- Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW: Polyamine analogue induction of the p53-p21(WAF1/CIP1)-Rb pathway and G(1) arrest in human melanoma cells. *Cancer Res.* 59:1278-1286 (1999).
- Krasagakis K, KrugerKrasagakes S, Fimmel S, Eberle J, Tholke D, vonderOhe M, Mansmann U, Orfanos CE: Desensitization of melanoma cells to autocrine TGF- β isoforms. *J.Cell Physiol* 178:179-187 (1999).
- *Krasilnikov M, Adler V, Fuchs SY, Dong Z, HaimovitzFriedman A, Herlyn M, Ronai Z: Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. *Mol.Carcinogen.* 24:64-69 (1999).
- Kroiss MM, Bosserhoff AK, Vogt T, Buettner R, Bogenrieder T, Landthaler M, Stolz W: Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. *Melanoma Res.* 8:504-509 (1998).
- Kuhn JA, McCarty TM: Malignant melanoma and the sentinel lymph node biopsy. *Cancer Invest* 17:39-46 (1999).
- Kumar R, Yoneda J, Fidler IJ, Dong ZY: GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. *J.LEUKOCYTE BIOL.* 65:102-108 (1999).
- La Vecchia C, Lucchini F, Negri E, Levi F: Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. *Int.J.Cancer* 81:62-66 (1999).
- Lage H, Christmann M, Kern MA, Dietel M, Pick M, Kaina B, Schadendorf D: Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O-6- methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. *Int.J.Cancer* 80:744-750 (1999).
- Lassau N, Mercier S, Koscielny S, Avril MF, Margulis A, Mamelle G, Duvillard P, Leclere J: Prognostic value of high-frequency sonography and color Doppler sonography for the preoperative assessment of melanomas. *Amer.J.Roentgenol.* 172:457-461 (1999).
- Lee V, Cree IA, Hungerford JL: Ring melanoma - a rare cause of refractory glaucoma. *Brit.J.Ophthalmol.* 83:194-198 (1999).
- Lejeune FJ: News on melanomas. *Bull.Cancer* 86:47-51 (1999).
- Lemke AJ, Hosten N, Bornfeld N, Bechrakis NE, Schuler A, Richter M, Stroszczynski C, Felix R: Uveal melanoma: Correlation of histopathologic and radiologic findings by using thin-section MR imaging with a surface coil. *Radiology* 210:775-783 (1999).
- Leong SPL, Enders-Zohr P, Zhou YM, Stuntebeck S, Habib FA, Allen RE, Sagebiel RW, Glassberg AB, Lowenberg DW, Hayes FA: Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. *J.Immunother.* 22:166-174 (1999).
- *Li MF, Xu F, Muller J, Huang XJ, Hearing VJ, Gorelik E: Loss of retrovirus production in JB/RH melanoma cells transfected with H-2K(B) and TAP-1 genes. *Virology* 253:230-240 (1999).
- Link EM: Targeting melanoma with At-211/I-131-methylene blue: Preclinical and clinical experience. *Hybridoma* 18:77-82 (1999).
- Liu L, Dilworth D, Gao LZ, Monzon J, Summers A, Lassam N, Hogg D: Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. *Nat.Genet.* 21:128-132 (1999).
- Loose IA, Jampol LM, OGrady R: Pigmented adenoma mimicking a juxtapapillary melanoma - A 20-year follow-up. *Arch.Ophthalmol.* 117:120-122 (1999).
- Lygidakis NJ, Safioleas M, Sgourakis G, Spentzouris N, Dedemadi G, Sotiropoulou P: Metastatic melanoma: Transplenic immunostimulation - A new therapeutical alternative for an ever-challenging disease. *HEPATO.GASTROENTEROL.* 46:148-156 (1999).
- Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. *J.Nat.Cancer Inst.* 91:359-367 (1999).
- Manici S, Sturmiolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP: Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. *J.Exp.Med.* 189:871-876 (1999).
- Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration (vol 42, pg 433, 1998). *Cancer Chemother.Pharmacol.* 43:439-440 (1999).
- Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Thin Cutaneous Malignant Melanomas (≤ 1.5 mm) - Identification of risk factors indicative of progression. *Cancer* 85:1067-1076 (1999).
- Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. *Hum.Pathol.* 30:339-344 (1999).
- McGregor JM: Naevi and melanomas. *Skin Diseases.After.Organ Transplantation* 139-144:-144 (1998).
- Merbs SL, Sidransky D: Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. *INVEST OPHTHALMOL.VISUAL SCI.* 40:779-783 (1999).
- Mijnhout GS, Pijpers R, Hoekstra OS, Teule GJJ, Borgstein PJ, Meijer S: Primary staging and follow-up of high risk melanoma patients with whole-body F-18-fluorodeoxyglucose positron emission tomography - Results of a prospective study of 100 patients. *Cancer* 85:1199-1200 (1999).
- Miller RW, Rabkin CS: Merkel cell carcinoma and melanoma: Etiological similarities and differences. *Cancer Epidem.Biomarker.Prev.* 8:153-158 (1999).
- Mondragon-Sanchez R, Barrera-Franco JL, Cordoba-Gutierrez H, Meneses-Garcia A: Repeat hepatic resection for recurrent metastatic melanoma. *HEPATO.GASTROENTEROL.* 46:459-461 (1999).
- Montaldo PG, Pagnan G, Pastorino F, Chiesa V, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M: N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells *in vitro* through induction of programmed cell death. *Int.J.Cancer* 81:262-267 (1999).

- Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I, Schroder JM, Schadendorf D: The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. *Brit.J.Cancer* 79:1025-1031 (1999).
- Mu Y, Kamada H, Kaneda Y, Yamamoto Y, Kodaira H, Tsunoda S, Tsutsumi Y, Maeda M, Kawasaki K, Nomizu M, Yamada Y, Mayumi T: Bioconjugation of laminin peptide YIGSR with poly(Styrene co-maleic acid) increases its antimetastatic effect on lung metastasis of B16-BL6 melanoma cells. *Biochem.Biophys.Res.Commun.* 255:75-79 (1999).
- Mukaiya M, Hirata K, Tarumi K, Takashima T, Hata F, Denno R, Koito K, Takahashi S, Satoh M: Surgical treatment for recurrent tumors of primary malignant melanoma of the esophagus: A case report and review of the literature. *HEPATO.GASTROENTEROL.* 46:295-298 (1999).
- Myers JN: Value of neck dissection in the treatment of patients with intermediate-thickness cutaneous malignant melanoma of the head and neck. *Arch.Otolaryngol.* 125:110-115 (1999).
- Nakamura K, Yamaguchi Y, Kagota S, Kwon YM, Shinozuka K, Kunitomo M: Inhibitory effect of *Cordyceps sinensis* on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngeneic mice. *JPN.J.PHARMACOL.* 79:335-341 (1999).
- Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, Plowman PN: Combination chemotherapy for choroidal melanoma: *ex vivo* sensitivity to treosulfan with gemcitabine or cytosine arabinoside. *Brit.J.Cancer* 79:1487-1493 (1999).
- Nestle FO, Burg G, Dummer R: New perspectives on immunobiology and immunotherapy of melanoma. *IMMUNOL.TODAY* 20:5-7 (1999).
- Noda S, Lammerding Koppel M, Oetting G, Drews U: Characterization of muscarinic receptors in the human melanoma cell line SK-Mel-28 via calcium mobilization. *Cancer Lett.* 133:107-114 (1998).
- Nordin P: Curettage-cryosurgery for non-melanoma skin cancer of the external ear: excellent 5-year results. *Brit.J.Dermatol.* 140:291-293 (1999).
- Olieman AFT, Lienard D, Eggermont AMM, Kroon BBR, Lejeune FJ, Hoekstra HJ, Koops HS: Hyperthermic isolated limb perfusion with tumor necrosis factor α , interferon γ , and melphalan for locally advanced nonmelanoma skin tumors of the extremities - A multicenter study. *Arch.Surg.* 134:303-307 (1999).
- Ophir R, Moalem G, Pecht M, Shashoua M, Rashid G, Ben Efraim S, Trainin N, Burstein Y, Keisari Y: THF- γ 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma. *J.Immunother.* 22:103-113 (1999).
- Ost D, Joseph C, Sogoloff H, Menezes G: Primary pulmonary melanoma: Case report and literature review. *Mayo Clin.Proc.* 74:62-66 (1999).
- Pacheco TR, Maxwell F, Wu MF, Na S, Maxwell IH: Use of a recombinant parvovirus to facilitate screening for human melanoma cell clones expressing tetracycline- responsive transactivators. *Gene* 229:125-129 (1999).
- Pagnan G, Montaldo PC, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M: GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. *Int.J.Cancer* 81:268-274 (1999).
- Pai SA, Cheung MCP, Romsdahl MM, Multani AS, Pathak S: Can genetic instability be studied at the single chromosome level in cancer cells? Evidence from human melanoma cells. *Cancer Genet.Cytogenet.* 109:51-57 (1999).
- Palmieri G, Strazzullo M, Ascierio PA, Satriano SMR, Daponte A, Castello G: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. *J.Clin.Oncol.* 17:304-311 (1999).
- Parmiani G: Gene modified human melanoma cell vaccines: new strategies. *EUROCANCER.* 98. 299-299:299 (1998).
- Parris CN, Harris JD, Griffin DK, Cuthbert AP, Silver AJR, Newbold RF: Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma. *Cancer Res.* 59:516-520 (1999).
- Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlege RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL: Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. *J.Exp.Med.* 189:757-765 (1999).
- Proebstle TM, Fuchs T, Scheibenbogen C, Sterry W, Keilholz U: Long-term outcome of treatment with dacarbazine, cisplatin, interferon- α and intravenous high dose interleukin-2 in poor risk melanoma patients. *Melanoma Res.* 8:557-563 (1998).
- Raaphorst GP, Ng CE, Yang DP: Thermal radiosensitization and repair inhibition in human melanoma cells: a comparison of survival and DNA double strand breaks. *INT.J.HYPERTHER.* 15 :17-27 (1999).
- Regauer S, Ott A, Berghold A, Beham A: CD44 expression in sinonasal melanomas: Is loss of isoform expression associated with advanced tumour stage? *J.Pathol.* 187:184-190 (1999).
- Rehany U, Rumelt S: Iridocorneal melanoma associated with type 1 neurofibromatosis - A clinicopathologic study. *OPHTHALMOLOGY* 106:614-618 (1999).
- Richards JM, Gale D, Mehta N, Lestingi T: Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. *J.Clin.Oncol.* 17:651-657 (1999).
- Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER: Frequent Nuclear/Cytoplasmic localization of β -catenin without exon 3 mutations in malignant melanoma. *AMER.J.PATHOL.* 154:325-329 (1999).
- Rinne D, Kaufmann P: Primary staging and follow-up of high risk melanoma patients with whole-body F-18-fluorodeoxyglucose positron emission tomography - Results of a prospective study of 100 patients - Reply. *Cancer* 85:1200-1201 (1999).
- Ritt MG, Wojcieszyn J, Modiano JF: Functional loss of p21/Waf-1 in a case of benign canine multicentric melanoma. *Vet.Pathol.* 35:94-101 (1998).
- Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G: A superagonist variant of peptide MART1/melan A(27-35) elicits anti-melanoma CD8(+) T cells with enhanced functional characteristics: Implication for more effective immunotherapy. *Cancer Res.* 59:301-306 (1999).
- Rizos H, Darmanian AP, Indsto JO, Shannon JA, Kefford RF, Mann GJ: Multiple abnormalities of the p16(INK4a)-pRb regulatory pathway in cultured melanoma cells. *Melanoma Res.* 9:10-19 (1999).
- Rodeck U, Nishiyama T, Mauviel A: Independent regulation of growth and SMAD-mediated transcription by transforming growth factor β in human melanoma cells. *Cancer Res.* 59:547-550 (1999).

- Rols MP, Delteil C, Golzio M, Teissie J: *In vitro* and *ex vivo* electrically mediated permeabilization and gene transfer in murine melanoma. *Bioelectrochem.Bioenerg.* 47:129-134 (1998).
- Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. *J.Clin.Oncol.* 17:968-975 (1999).
- Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M: Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. *Int.J.Cancer* 81:156-163 (1999).
- Rosso S, Zanetti R, Pippione M, SanchoGarnier H: Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. *Melanoma Res.* 8:573-583 (1998).
- Ruan ST, Raj BKM, Lloyd KO: Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells. *J.Neurochem.* 72:514-521 (1999).
- Ruegg C, Oguey D, Lejeune F: Death to endothelial cells, death to melanoma? *Melanoma Res.* 9:2-3 (1999).
- Rusciano D, Lorenzoni P, Burger MM: Regulation of c-met expression in B16 murine melanoma cells by melanocyte stimulating hormone. *J.Cell Sci.* 112:623-630 (1999).
- Saenz NC, SaenzBadillos J, Busam K, LaQuaglia MP, Corbally M, Brady MS: Childhood melanoma survival. *Cancer* 85:750-754 (1999).
- Salpietro FM, Alafaci C, Grasso G, Tomasello F: Primary melanoma - Response. *J.Neurosurg.* 90:609-610 (1999).
- Sander B, Karlsson P, Rosdahl I, Westermarck P, Boeryd B: Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: A clinico-pathological study of 130 cases. *Int.J.Cancer* 80:646-651 (1999).
- Sardi I, Moretti S, Ponchietti R, Arrigucci S, Guazzelli R, Montali E: The role of the detection of hematogenous micrometastasis in prostate adenocarcinoma and malignant melanoma by RT-PCR. *Int.J.Mol.Med.* 3:417-419 (1999).
- Savitz MH: Primary melanoma. *J.Neurosurg.* 90:609 (1999).
- Schlagbauer-Wadl H, Griffioen M, van Elsas A, Schrier PI, Pustelnik T, Eichler HG, Wolff K, Pehamberger H, Jansen B: Influence of increased c-Myc expression on the growth characteristics of human melanoma. *J.INVEST DERMATOL.* 112:332-336 (1999).
- Selvaag E, Loeb M, Larsen TE, Thune P: Cutaneous malignant melanoma in Norway: experiences from the Norwegian Melanoma Project. *Melanoma Res.* 9:92-95 (1999).
- Semb KA, Aamdal S, Bohmann T, Lucas C, Gerard B: Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. *Melanoma Res.* 8:565-572 (1998).
- Serova-Sinilnikova O, Egan K, Boutrand L, Stoppa-Lyonnet D, Desjardins L, Levy C, Bignon YJ, Lasset C, Haguenaer O, Goldgar D, Lenoir GM: Implication of germline BRCA2 gene mutations for the occurrence of ocular melanoma and pancreatic cancer. *EUROCANER.* 98. 113-114:114 (1998).
- Serrone L, Horsey P: The chemoresistance of human malignant melanoma: an update. *Melanoma Res.* 9:51-58 (1999).
- Shaw HM, Thompson JF: Superior survival of young women with malignant melanoma. *AMER.J.SURG.* 177:176-176 (1999).
- Smith JAE, Whatley PM, Redburn JC: Improving survival of melanoma patients in Europe since 1978. *Eur.J.Cancer* 34:2197-2203 (1998).
- *Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, Taylor SA, Balcerzak SP, Meyskens FL : A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group Study. *Cancer J.Sci.Am.* 5:41-47 (1999).
- Spencer JM: Nail-apparatus melanoma. *Lancet* 353:84-85 (1999).
- Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH: Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. *Blood* 93:1634-1642 (1999).
- Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison CL, Moen RC, Gaudie J, Graham FL: Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. *Gene Therapy.* 6:350-363 (1999).
- Strohal R, Brna C, Mossbacher U, Fischer G, Pehamberger H, Stingl G: First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites (Vol 111, pg 1085, 1998). *J.INVEST DERMATOL.* 112: 256 (1999).
- *Syngal S, Kaptain S, O'Neill MJ, Isselbacher KJ, Sober AJ, Chung DC, Haluska FG: A 50-year-old woman with severe diarrhea during radiation treatment for resected metastatic melanoma Cutaneous melanoma metastasized to the gastrointestinal tract, with protein-losing enteropathy. Adrenal cortical adenoma. *N.Engl.J.Med.* 340:789-796 (1999).
- Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF: IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. *J.INVEST DERMATOL.* 112:205-209 (1999).
- Terayama K, Hirokawa M, Shimizu M, Mikami Y, Kanahara T, Manabe T: Balloon melanoma cells mimicking foamy histiocytes. *Acta Cytol.* 43:325-326 (1999).
- Timar J, Trikha M, Szekeres K, Bazaz R, Honn K: Expression and function of the high affinity α IIb β 3 integrin in murine melanoma cells. *Clin.Exp.Metastas.* 16:437-445 (1998).
- Tsao H, Zhang X, Majewski P, Haluska FG: Mutational and expression analysis of the p73 gene in melanoma cell lines. *Cancer Res.* 59:172-174 (1999).
- Tschugguel W, Pustelnik T, Lass H, Mildner M, Weninger W, Schneeberger C, Jansen B, Tschachler E, Waldhor T, Huber JC, Pehamberger H: Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. *Brit.J.Cancer* 79:1609-1612 (1999).
- Vaideswar P, Prabhat DP, Sivaraman A: Epidermal inclusion cyst with melanoma-like melanophagic proliferation. *Acta Dermatol.Venereol.* 79:88 (1999).
- Van der Rhee HJ, Spek-Keijser LMT, Van Westering R, Coebergh JWW: Increase in and stabilization of incidence and mortality of primary cutaneous malignant melanoma in western Netherlands, 1980-95. *Brit.J.Dermatol.* 140:463-467 (1999).
- Vinceti M, Bergomi M, Borciani N, Serra L, Vivoli G: Rising melanoma incidence in an Italian community from 1986 to 1997. *Melanoma Res.* 9:97-103 (1999).

- Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K, Pyrhonen S: Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. *Melanoma Res.* 9:59-68 (1999).
- von Leoprechting A, van der BP, Pahl HL, Aruffo A, Simon JC: Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. *Cancer Res.* 59:1287-1294 (1999).
- Wang BY, Chen YB, Ayalon O, Bender J, Garen A: Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. *Proc.Nat.Acad.Sci.Usa* 96:1627-1632 (1999).
- Westbrook KC, Klimberg VS: Sentinel lymph node biopsy for melanoma - Discussion. *AMER.J.SURG.* 176:547 (1998).
- Wojtukiewicz MZ, Rucinska M, Kloczko J, Dib A, Galar M: Profiles of plasma serpins in patients with advanced malignant melanoma, gastric cancer and breast cancer. *Haemostasis* 28:7-13 (1998).
- Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK: *In vivo* sensitivity of human melanoma to tumor necrosis factor (TNF)- α , is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). *Cancer Res.* 59:205-212 (1999).
- Yang Q, O'Hanlon D, Heizmann CW, Marks A: Demonstration of heterodimer formation between S100B and S100A6 in the yeast two-hybrid system and human melanoma. *Exp.Cell Res.* 246:501-509 (1999).
- Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. *J.Immunol.* 162:2227-2234 (1999).
- Yudoh K, Matsuno H, Kimura T: 1 α ,25-dihydroxyvitamin D-3 inhibits *in vitro* invasiveness through the extracellular matrix and *in vivo* pulmonary metastasis of B16 mouse melanoma. *J.LAB CLIN.MED.* 133:120-128 (1999).
- Zendman AJW, Cornelissen IMHA, Weidle UH, Ruiter DJ, van Muijen GNP: TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential. *FEBS Lett.* 446:292-298 (1999).
- Zerp SF, vanElsas A, Peltenburg LTC, Schrier PI: p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. *Brit.J.Cancer* 79:921-926 (1999).
- Zhang M, Stevens G: Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines. *Melanoma Res.* 8:510-515 (1998).
- Zhao XX, Wakamatsu Y, Shibahara M, Nomura N, Geltinger C, Nakahara T, Murata T, Yokoyama KK: Mannosylerythritol lipid is a potent inducer of apoptosis and differentiation of mouse melanoma cells in culture. *Cancer Res.* 59:482-486 (1999).
- Zorn E, Hercend T: A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. *Eur.J.Immunol.* 29:592-601 (1999).
- Zorn E, Hercend T: A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. *Eur.J.Immunol.* 29:602-607 (1999).

MSH, POMC, GROWTH FACTORS & RECEPTORS

- Abe M, Itoh MT, Miyata M, Ishikawa S, Sumi Y: Detection of melatonin, its precursors and related enzyme activities in rabbit lens. *Exp.Eye Res.* 68:255-262 (1999).
- Brandenburger Y, Rose K, Bagutti C, Eberle AN: Synthesis and receptor binding analysis of thirteen oligomeric α -MSH analogs. *J.Recept.Signal.Transduct.Res.* 19:467-480 (1999).
- Carrithers MD, Marotti LA, Yoshimura A, Lerner MR: A melanophore-based screening assay for erythropoietin receptors. *J.BIOMOL.SCREEN.* 4:9-14 (1999).
- Edwards CMB, Abusnana S, Sunter D, Murphy KG, Ghate MA, Bloom SR: The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. *J.Endocrinol.* 160:R7-R12 (1999).
- *Englaro W, Bahadoran P, Bertolotto C, Busca R, Derijard B, Livolsi A, Peyron JF, Ortonne JP, Ballotti R: Tumor necrosis factor α -mediated inhibition of melanogenesis is dependent on nuclear factor κ B activation. *Oncogene* 18:1553-1559 (1999).
- Fisher SL, Yagaloff KA, Burn P: Melanocortin and leptin signaling systems: Central regulation of catabolic energy balance. *J.Recept.Signal.Transduct.Res.* 19:203-216 (1999).
- Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. *Hypertension* 33:542-547 (1999).
- Heijmen PS, Klis SFL, DeGroot JCMJ, Smoorenburg GF: Cisplatin ototoxicity and the possibly protective effect of α -melanocyte stimulating hormone. *Hear.Res.* 128:27-39 (1999).
- Heizmann G, Hildebrand P, Tanner H, Ketterer S, Pansky A, Froidevaux S, Beglinger C, Eberle AN: A combinatorial peptoid library for the identification of novel MSH and GRP/bombesin receptor ligands. *J.Recept.Signal.Transduct.Res.* 19:449-466 (1999).
- Hintermann E, Drozd R, Tanner H, Eberle AN: Synthesis and characterization of new radioligands for the mammalian melanin-concentrating hormone (MCH) receptor. *J.Recept.Signal.Transduct.Res.* 19:411-422 (1999).
- Kouki T, Kawamura K, Kikuyama S: Lack of inhibitory control of melanophore-stimulating hormone secretion in the larval toad, *Bufo japonicus*. *Zool.Sci.* 15:749-752 (1998).
- Masini MA, Sturla M, Pestarino M, Facchinetti F, Gallinelli A, Uva BM: Proopiomelanocortin (POMC) mRNA and POMC-derived peptides immunolocalization in the skin of *Protopterus annectens*, an African lungfish. *Peptides* 20:87-91 (1999).
- Murata J, Ayukawa K, Ogasawara M, Watanabe H, Saiki I: Induction of autocrine factor inhibiting cell motility from murine B16-BL6 melanoma cells by α -melanocyte stimulating hormone. *Int.J.Cancer* 80:889-895 (1999).
- Rehli M, DenElzen N, Cassidy AI, Ostrowski MC, Hume DA: Cloning and characterization of the murine genes for bHLH- ZIP transcription factors TFEC and TFEB reveal a common gene organization for all MiT subfamily members. *Genomics* 56:111-120 (1999).

- Rehli M, Lichanska A, Cassady AI, Ostrowski MC, Hume DA: TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. *J.Immunol.* 162 :1559-1565 (1999).
- Sato M, Morii E, TakebayashiSuzuki K, Yasui N, Ochi T, Kitamura Y, Nomura S: Microphthalmia-associated transcription factor interacts with PU.1 and c-Fos: Determination of their subcellular localization. *Biochem.Biophys.Res.Commun.* 254:384-387 (1999).
- *Slominski A, Heasley D, Mazurkiewicz JE, Ermak G, Baker J, Carlson JA: Expression of proopiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH) and adrenocorticotrophic hormone (ACTH) peptides in skin of basal cell carcinoma patients. *Hum.Pathol.* 30:208-215 (1999).
- Soriani O, Le Foll F, Roman F, Monnet FP, Vaudry H, Cazin L: A-current down-modulated by a receptor in frog pituitary melanotrope cells through a G protein-dependent pathway. *J.Pharmacol.Exp.Ther.* 289:321-328 (1999).
- Teh MT, Sugden D: The putative melatonin receptor antagonist GR128107 is a partial agonist on *Xenopus laevis* melanophores. *BRIT.J.PHARMACOL.* 126:1237-1245 (1999).
- VanderKraan M, Tatro JB, Entwistle ML, Brakkee JH, Burbach JPH, Adan RAH, Gispen WH: Expression of melanocortin receptors and pro- opiomelanocortin in the rat spinal cord in relation to neurotrophic effects of melanocortins. *Mol.Brain Res.* 63:276-286 (1999).
- Viale A, Ortolà C, Hervieu G, Furuta M, Barbero P, Steiner DF, Seidah NG , Nahon JL: Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals. *J.Biol.Chem.* 274:6536-6545 (1999).

DEVELOPMENTAL BIOLOGY

- Devalaraja MN, Wang DZ, Ballard DW, Richmond A: Elevated constitutive I κ B kinase activity and I κ B- α phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO- α transcription. *Cancer Res.* 59:1372-1377 (1999).
- Fujimura T, Furukawa H, Doi Y, Makishima K, Fujimoto S: Immunoreactivity of endothelins and endothelin receptor in the stria vascularis of the mouse cochlea. *Hear.Res.* 128:135-146 (1999).
- *Gunn TM, Miller KA, He L, Hyman RV, Davis RW, Azarani A, Schlossman SF, Duke-Cohan JS, Barsh GS: The mouse mahogany locus encodes a transmembrane form of human attractin. *Nature* 398:152-156 (1999).
- Kerstjens-Frederikse WS, Hofstra RMW, van Essen AJ, Meijers JHC , Buys CHCM: A Hirschsprung disease locus at 22q11? *J.Med.Genet.* 36:221-224 (1999).
- Nash WG, Wienberg J, Ferguson-Smith MA, Menninger JC, O'Brien SJ: Comparative genomics: tracking chromosome evolution in the family Ursidae using reciprocal chromosome painting. *Cytogenet.Cell Genet.* 83:182-192 (1998).
- Ortiz M, Wine JW, Lohrey N, Ruscetti FW, Spence SE, Keller JR: Functional characterization of a novel hematopoietic stem cell and its place in the c-kit maturation pathway in bone marrow cell development. *Immunity.* 10:173-182 (1999).
- Reeves FC, Burdge GC, Fredericks WJ, Rauscher FJ, Lillycrop KA: Induction of antisense Pax-3 expression leads to the rapid morphological differentiation of neuronal cells and an altered response to the mitogenic growth factor bFGF. *J.Cell Sci.* 112:253-261 (1999).
- Schmidt A, Tief K, Yavuzer U, Beermann F: Ectopic expression of RET results in microphthalmia and tumors in the retinal pigment epithelium. *Int.J.Cancer* 80:600-605 (1999).
- *Southard-Smith EM, Angrist M, Ellison JS, Agarwala R, Baxevanis AD, Chakravarti A, Pavan WJ: The Sox10(Dom) mouse: Modeling the genetic variation of Waardenburg-Shah (WS4) syndrome. *Genome Res.* 9:215-225 (1999).
- Spence S, Anderson C, Cukierski M, Patrick D: Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat. *Reprod.Toxicol.* 13:15-29 (1999).
- Tsutsumi M, Liang C, Jones PA: Novel endothelin B receptor transcripts with the potential of generating a new receptor. *Gene* 228:43-49 (1999).
- Zhang SC, Fedoroff S: Expression of stem cell factor and c-kit receptor in neural cells after brain injury. *Acta Neuropathol.* 97:393-398 (1999).

DIFFERENTIATION

- Albinism provides more clues to early African history to complement the lessons of language. *S.Afr.J.Sci.* 94:544-545 (1998).
- Ballarin L, Cima F, Sabbadin A: Phenoloxidase and cytotoxicity in the compound ascidian *Botryllus schlosseri*. *Develop.Comp Immunol.* 22:479-492 (1998).
- Bazhan NM, Yakovleva TV, Makarova EN: Agouti locus may influence reproduction under food deprivation in the water vole (*Arvicola terrestris*). *J.Exp.Zool.* 283:573-579 (1999).
- Bubacco L, Salgado J, Tepper AWJW, Vijgenboom E, Canters GW: H-1 NMR spectroscopy of the binuclear Cu(II) active site of *Streptomyces antibioticus* tyrosinase. *FEBS Lett.* 442:215-220 (1999).
- De Sepulveda P, Okkenhaug K, La Rose J, Hawley RG, Dubreuil P, Rottapel R: Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation. *EMBO J.* 18:904-915 (1999).
- *Fang D, Setaluri V: Role of microphthalmia transcription factor in regulation of melanocyte differentiation marker TRP-1. *Biochem.Biophys.Res.Commun.* 256:657-663 (1999).
- Fulton AB: Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). *Arch.Ophthalmol.* 117:251-252 (1999).
- Galileo DS, Hunter K, Smith SB: Stable and efficient gene transfer into the mutant retinal pigment epithelial cells of the Mitf(vit) mouse using a lentiviral vector. *Curr.Eye Res.* 18:135-142 (1999).
- Gollas-Galvan T, Hernandez-Lopez J , Vargas-Albores F: Prophenoloxidase from brown shrimp *Panaeus californiensis* hemocytes. *COMP BIOCHEM.PHYSIOL PT.B* 122:77-82 (1999).

- HaskellLuevano C, Chen PL, Li C, Chang K, Smith MS, Cameron JL, Cone RD: Characterization of the neuroanatomical distribution of agouti-related protein immunoreactivity in the rhesus monkey and the rat. *Endocrinology* 140:1408-1415 (1999).
- Hayashi T, Kageyama Y, Ishizaka K, Tsujii T, Oshima H: True hermaphroditism associated with microphthalmia. *Eur.J.Endocrinology* 140:62-65 (1999).
- Huang JD, Brady ST, Richards BW, Stenoien D, Resau JH, Copeland NG, Jenkins NA: Direct interaction of microtubule- and actin-based transport motors. *Nature* 397:267-270 (1999).
- Huber M, Helgason CD, Scheid MP, Duronio V, Humphries RK, Krystal G: Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. *EMBO J.* 17:7311-7319 (1998).
- JimenezCervantes C, MartinezEsparza M, Solano F, Lozano JA, GarciaBorron J: Molecular interactions within the melanogenic complex: Formation of heterodimers of tyrosinase and TRP1 from B16 mouse melanoma. *Biochem.Biophys.Res.Commun.* 253:761-767 (1998).
- Kaatz H, Streffer K, Wollenberger U, Peter MG: Inhibition of mushroom tyrosinase by kojic acid octanoates. *Z.NATURFORSCH.C.* 54:70-74 (1999).
- Kato M, Liu W, Akhand AA, Dai Y, Ohbayashi M, Tuzuki T, Suzuki H, Isobe K, Takahashi M, Nakashima I: Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I ret transgenic mouse lines. *Oncogene* 18:837-842 (1999).
- Kono T, Migita T, Koyama S, Seki I: Another observation of microphthalmia in an XX male: microphthalmia with linear skin defects syndrome without linear skin lesions. *J.HUM.GENET.* 44:63-68 (1999).
- Kubo I, Kinshori I: 2-hydroxy-4-methoxybenzaldehyde: A potent tyrosinase inhibitor from African medicinal plants. *Planta Med.* 65:19-22 (1999).
- *Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ : Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. *J.Biol.Chem.* 274:3268-3271 (1999).
- Mizuno TM, Mobbs CV: Hypothalamic Agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. *Endocrinology* 140:814-817 (1999).
- *Oetting WS, King RA: Molecular basis of albinism: Mutations and polymorphisms of pigmentation genes associated with albinism. *Hum.Mutat.* 13:99-115 (1999).
- *Orlow SJ, Brilliant MH: The pink-eyed dilution locus controls the biogenesis of melanosomes and levels of melanosomal proteins in the eye. *Exp.Eye Res.* 68:147-154 (1999).
- Rompel A, Fischer H, Meiwes D, Buldt-Karentzopoulos K, Dillinger R, Tuzek F, Witzel H, Krebs B: Purification and spectroscopic studies on catechol oxidases from *Lycopus europaeus* and *Populus nigra*: Evidence for a dinuclear copper center of type 3 and spectroscopic similarities to tyrosinase and hemocyanin. *J.BIOL.INORG.CHEM.* 4:56-63 (1999).
- Rosenberg T, Schwartz M: X-linked ocular albinism: prevalence and mutations - a national study. *Eur.J.Human Genet.* 6:570-577 (1998).
- Simmen T, Schmidt A, Hunziker W, Beermann F: The tyrosinase tail mediates sorting to the lysosomal compartment in MDCK cells via a di-leucine and a tyrosine- based signal. *J.Cell Sci.* 112:45-53 (1999).
- Steiner U, Schliemann W, Bohm H, Strack D: Tyrosinase involved in betalain biosynthesis of higher plants. *Planta* 208:114-124 (1999).
- Stephenson DA, Novak EK, Chapman VM: Analysis of the Kit and Pdgfra genes in the patch-extended (Ph-e) mutation. *Genet.Res.* 72:205-210 (1998).
- Sugimoto H, Taniguchi M, Nakagawa A, Tanaka I, Suzuki M, Nishihira J: Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 angstrom resolution. *BIOCHEMISTRY USA* 38:3268-3279 (1999).
- Tollemer H, Teitsma CA, Leprince J, Bailhache T, Vandesande F, Kah O, Tonon MC, Vaudry H: Immunohistochemical localization and biochemical characterization of two novel decapeptides derived from POMC-A in the trout hypothalamus. *Cell Tissue Res.* 295:409-417 (1999).
- Tota MR, Smith TS, Mao C, MacNeil T, Mosley RT, Vanderploeg LHT, Fong TM: Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors. *BIOCHEMISTRY USA* 38:897-904 (1999).
- Toyofuku K, Wada I, Hirosaki K, Park JS, Hori Y, Jimbow K: Promotion of tyrosinase folding in COS 7 cells by calnexin. *J.Biochem.Tokyo* 125:82-89 (1999).
- Tungel R, Rinken T, Rinken A, Tenno T: Immobilisation and kinetic study of tyrosinase for biosensor construction. *Anal.Lett.* 32:235-249 (1999).
- Zhang XD, vanLeeuwen J, Wichers HJ, Flurkey WH: Characterization of tyrosinase from the cap flesh of portabella mushrooms. *J.Agr.Food Chem.* 47:374-378 (1999).

MISCELLANEOUS

- DuranMcKinster C, RodriguezJurado R, Ridaura C, OrozcoCovarrubias MADL, Tamayo L, RuizMaldonado R: Elejalde syndrome - A melanolysosomal neurocutaneous syndrome - Clinical and morphological findings in 7 patients. *Arch.Dermatol.* 135:182-186 (1999).
- Elgart GW, Hanly A, Busso M, Spencer JM: Bednar tumor (Pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: Immunochemical findings and therapy. *J.Amer.Acad.Dermatol.* 40:315-317 (1999).
- Faure V, Hecquet C, Courtois Y, Goureau O: Role of interferon regulatory factor-1 and mitogen- activated protein kinase pathways in the induction of nitric oxide synthase-2 in retinal pigmented epithelial cells. *J.Biol.Chem.* 274:4794-4800 (1999).
- Fischer AJ, Stell WK: Nitric oxide synthase-containing cells in the retina, pigmented epithelium, choroid, and sclera of the chick eye. *J.COMP NEUROL.* 405:1-14 (1999).
- Hjelmeland LM: Senescence of the retinal pigmented epithelium. *INVEST OPHTHALMOL.VISUAL SCI.* 40:1-2 (1999).

- Iwahara K, Koike M, Ogawa H: Pigmented follicular cyst showing degenerating pigmented hair shafts on histology. *Brit.J.Dermatol.* 140:364-365 (1999).
- Kittler H, Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M: Morphologic changes of pigmented skin lesions: A useful extension of the ABCD rule for dermatoscopy. *J.Amer.Acad.Dermatol.* 40:558-562 (1999).
- Tang Q, Rice DS, Goldowitz D: Disrupted retinal development in the embryonic belly spot and tail mutant mouse. *DEVELOP.BIOL.* 207:239-255 (1999).